Unity biotechnology, inc. (UBX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-91,448

-82,177

-86,066

-82,703

-79,032

-76,398

-67,025

-60,429

-51,855

-44,656

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,929

2,663

2,514

2,437

2,315

2,180

2,052

1,939

1,712

1,304

0

0

0

Net accretion and amortization of premium and discounts on marketable securities

848

1,151

1,404

1,518

1,288

955

0

0

0

-

-

-

-

Amortization of premium and discounts on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

0

Stock-based compensation

12,172

10,852

10,280

9,174

10,068

9,441

8,462

6,304

3,991

3,034

0

0

0

Non-cash rent expense

0

-

-

-

0

-

-

-

-

-

-

-

-

Impairment of long-lived assets

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of strategic investment

0

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of tenant improvement allowance

-

1,275

1,022

770

605

605

608

608

606

605

0

0

0

Change in fair value of contingent consideration

0

-

-

-

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Contribution receivable

-

-

-

-

-

-1,382

0

0

0

-

-

-

-

Prepaid expenses and other current assets

234

169

246

946

945

842

963

895

136

746

0

0

0

Other long-term assets

-7

31

-477

-478

609

604

1,107

1,101

7

-23

0

0

0

Accounts payable

-796

-227

1,806

3,252

-378

2,228

-2,163

-1,233

1,983

1,198

0

0

0

Accrued compensation

556

2,114

833

800

716

1,610

0

0

0

-

-

-

-

Accrued compensation

-

-

-

-

-

-

-

-

-

-

-

-

0

Accrued and other current liabilities

-762

-587

104

-555

1,272

1,446

2,611

2,454

1,563

1,258

0

0

0

Deferred rent, net of current portion

-

2,461

1,356

182

-192

-93

0

0

0

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash used in operating activities

-76,898

-72,421

-69,536

-66,588

-65,336

-56,623

-55,417

-50,653

-42,381

-38,358

0

0

0

Investing activities
Purchase of marketable securities

138,166

119,270

128,174

116,982

215,915

204,086

180,240

161,983

81,476

134,465

0

0

0

Maturities of marketable securities

171,138

188,809

201,535

173,640

172,692

133,644

0

0

0

-

-

-

-

Purchase of property and equipment

1,413

1,586

1,425

1,175

1,370

1,264

1,142

1,231

1,496

1,689

0

0

0

Net cash provided by investing activities

31,559

67,953

71,436

54,983

-45,093

-72,206

-62,274

-59,631

-13,850

-86,305

0

0

0

Financing activities
Proceeds from issuance of common stock under ATM Offering Program, net of issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

59,881

59,898

59,886

89,834

42,867

0

0

0

Proceeds from issuance of common stock upon exercise of stock options, net of repurchases

0

-

-

-

0

-

-

-

0

-

-

-

-

Other financing cash flows

0

-

-

-

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options, net of repurchases

-

-

-

-

-

-

-

-

-

-

-

-

0

Payment of initial public offering costs

-

-

-

-

-

3,201

0

0

0

-

-

-

-

Payments made on capital lease obligations

-

-

-

-

-

74

0

0

0

-

-

-

-

Net cash provided by financing activities

36,149

27,438

6,867

1,449

82,820

136,930

136,621

136,545

89,181

42,775

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-9,190

22,970

0

0

0

-

-

-

-

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

32,950

-

0

0

0

Supplemental Disclosures of Non-Cash Investing and Financing Activities
Property and equipment included in accounts payable and accrued liabilities

796

565

148

150

278

241

166

-76

222

314

0

0

0

Issuance of shares in settlement of share-based liability

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock to settle contingent consideration liability

-

-

-

-

0

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

Receipt of promissory note from related party for purchase of common stock

-

-

-

-

-

390

0

0

0

-

-

-

-

Receipt of promissory note from employees for purchase of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-